Mustang Bio (NASDAQ:MBIO) Upgraded to “Hold” at Wall Street Zen

Mustang Bio (NASDAQ:MBIO) was upgraded by Wall Street Zen to a “hold” rating in a research note issued on Friday.

Mustang Bio Trading Down 6.0%

Mustang Bio stock opened at $2.18 on Friday. Mustang Bio has a 1-year low of $0.89 and a 1-year high of $24.00. The firm has a market capitalization of $9.55 million, a price-to-earnings ratio of -0.03 and a beta of 2.16. The firm has a 50 day simple moving average of $1.48 and a 200 day simple moving average of $2.55.

Mustang Bio (NASDAQ:MBIO) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) EPS for the quarter. On average, equities research analysts forecast that Mustang Bio will post -35 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Mustang Bio stock. Anson Funds Management LP bought a new position in Mustang Bio, Inc. (NASDAQ:MBIO) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 45,716 shares of the company’s stock, valued at approximately $57,000. Anson Funds Management LP owned approximately 1.04% of Mustang Bio as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 9.95% of the company’s stock.

Mustang Bio Company Profile

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.